All Stories

  1. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

    Article • Inflammatory Bowel Diseases, March 2026, Oxford University Press (OUP)

    Taku Kobayashi

  2. Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis

    Article • Journal of Crohn s and Colitis, March 2026, Oxford University Press (OUP)

    Taku Kobayashi

  3. Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis

    Article • Journal of Crohn s and Colitis, January 2026, Oxford University Press (OUP)

    Taku Kobayashi

  4. Mechanism of IL-10 production via IL-1R in gut macrophages

    Article • Biochemical and Biophysical Research Communications, October 2025, Elsevier

    Taku Kobayashi

  5. An Early Phase 2 Double-Blind, Placebo-Controlled Study of E6011, a Novel Anti-Fractalkine Antibody, in Patients with Crohn’s Disease

    Article • Inflammatory Intestinal Diseases, September 2025, Karger Publishers

    Taku Kobayashi

  6. Early reduction in rectal wall thickness on transperineal ultrasound predicts mucosal healing in ulcerative colitis

    Article • Journal of Crohn s and Colitis, August 2025, Oxford University Press (OUP)

    Taku Kobayashi

  7. Patient preferences for advanced therapies in ulcerative colitis using conjoint analysis

    Article • Intestinal Research, July 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  8. Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study

    Article • Intestinal Research, July 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  9. Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

    Article • Journal of Crohn s and Colitis, July 2025, Oxford University Press (OUP)

    Taku Kobayashi

  10. Editorial: Time to EXIT? When Less Is More in IBD Management

    Article • Alimentary Pharmacology & Therapeutics, June 2025, Wiley

    Taku Kobayashi

  11. The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study

    Article • Intestinal Research, June 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  12. Real‐World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study

    Article • Journal of Gastroenterology and Hepatology, May 2025, Wiley

    Taku Kobayashi

  13. Lifestyle restrictions are associated with impaired quality of life but not reduction in relapse in ulcerative colitis

    Article • Intestinal Research, May 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  14. Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU

    Article • Gut, May 2025, BMJ

    Taku Kobayashi

  15. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

    Article • Journal of Crohn s and Colitis, May 2025, Oxford University Press (OUP)

    Taku Kobayashi

  16. Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study

    Article • Intestinal Research, April 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  17. Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis

    Article • Crohn s & Colitis 360, April 2025, Oxford University Press (OUP)

    Taku Kobayashi

  18. Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study

    Article • Advances in Therapy, February 2025, Springer Science + Business Media

    Taku Kobayashi

  19. Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

    Article • Intestinal Research, January 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  20. Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study

    Article • Intestinal Research, January 2025, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  21. Editorial: Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease: Its Potential in Early‐Stage Disease—Authors' Reply

    Article • Alimentary Pharmacology & Therapeutics, January 2025, Wiley

    Taku Kobayashi

  22. Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study

    Article • United European Gastroenterology Journal, November 2024, Wiley

    Taku Kobayashi

  23. Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis

    Article • Intestinal Research, October 2024, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  24. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

    Article • Inflammatory Bowel Diseases, October 2024, Oxford University Press (OUP)

    Taku Kobayashi

  25. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus

    Article • Digestive and Liver Disease, August 2024, Elsevier

    Taku Kobayashi

  26. A case of cytomegalovirus esophagitis difficult to distinguish from Crohn’s disease exacerbation

    Article • Clinical Journal of Gastroenterology, May 2024, Springer Science + Business Media

    Taku Kobayashi

  27. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies

    Article • Intestinal Research, April 2024, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  28. Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia?

    Article • Alimentary Pharmacology & Therapeutics, April 2024, Wiley

    Taku Kobayashi

  29. Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights

    Article • Alimentary Pharmacology & Therapeutics, March 2024, Wiley

    Taku Kobayashi

  30. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

    Article • Inflammatory Bowel Diseases, March 2024, Oxford University Press (OUP)

    Taku Kobayashi

  31. Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety

    Article • Alimentary Pharmacology & Therapeutics, January 2024, Wiley

    Taku Kobayashi

  32. Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn’s Disease

    Article • Inflammatory Bowel Diseases, November 2023, Oxford University Press (OUP)

    Taku Kobayashi

  33. Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study

    Article • Journal of Gastroenterology and Hepatology, October 2023, Wiley

    Taku Kobayashi

  34. Artificial intelligence quantifying endoscopic severity of ulcerative colitis in gradation scale

    Article • Digestive Endoscopy, October 2023, Wiley

    Taku Kobayashi

  35. Letter: Transperineal ultrasonography for ulcerative proctitis—Applicability in the pregnant population? Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, September 2023, Wiley

    Taku Kobayashi

  36. Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT

    Article • Journal of Gastroenterology, August 2023, Springer Science + Business Media

    Taku Kobayashi

  37. Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis

    Article • Intestinal Research, April 2023, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  38. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes

    Article • Journal of Crohn s and Colitis, April 2023, Oxford University Press (OUP)

    Taku Kobayashi

  39. A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease

    Article • Journal of Crohn s and Colitis, March 2023, Oxford University Press (OUP)

    Taku Kobayashi

  40. Reducing Health Anxiety in Patients With Inflammatory Bowel Disease Using Video Testimonials: Pilot Assessment of a Video Intervention

    Article • JMIR Formative Research, February 2023, JMIR Publications Inc.

    Taku Kobayashi

  41. iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis

    Article • Journal of Clinical Medicine, February 2023, MDPI AG

    Taku Kobayashi

  42. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

    Article • Intestinal Research, January 2023, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  43. Author Correction: Improving IBD outcomes in the era of many treatment options

    Article • Nature Reviews Gastroenterology & Hepatology, January 2023, Springer Science + Business Media

    Taku Kobayashi

  44. Improving IBD outcomes in the era of many treatment options

    Article • Nature Reviews Gastroenterology & Hepatology, January 2023, Springer Science + Business Media

    Taku Kobayashi

  45. Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn’s Disease

    Article • Inflammatory Intestinal Diseases, January 2023, Karger Publishers

    Taku Kobayashi

  46. Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease

    Article • Digestion, November 2022, Karger Publishers

    Taku Kobayashi

  47. De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease

    Article • Gut and Liver, November 2022, The Editorial Office of Gut and Liver

    Taku Kobayashi

  48. Early phase partial Mayo score following golimumab treatment is associated with endoscopic improvement at 1-year in ulcerative colitis; A post hoc analysis of PURSUIT-J randomized controlled trial

    Article • Inflammatory Intestinal Diseases, August 2022, Karger Publishers

    Katsumasa Nagano, Taku Kobayashi

  49. Hospital Senpai: A pilot for reducing health anxiety in inflammatory bowel disease patients using video testimonials (Preprint)

    Article • June 2022, JMIR Publications Inc.

    Taku Kobayashi

  50. Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed? Authorsʼ reply

    Article • Alimentary Pharmacology & Therapeutics, April 2022, Wiley

    Taku Kobayashi

  51. Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis—an accurate early predictor of response to treatment. Authors' reply

    Article • Alimentary Pharmacology & Therapeutics, April 2022, Wiley

    Taku Kobayashi

  52. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, February 2022, Wiley

    Taku Kobayashi

  53. Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases

    Article • Digestion, January 2022, Karger Publishers

    Taku Kobayashi

  54. OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study

    Article • Journal of Crohn s and Colitis, January 2022, Oxford University Press (OUP)

    Taku Kobayashi

  55. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis

    Article • Intestinal Research, October 2021, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  56. Development of algorithms for identifying patients with Crohn’s disease in the Japanese health insurance claims database

    Article • PLOS One, October 2021, PLOS

    Taku Kobayashi

  57. Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation

    Article • Journal of Gastroenterology, September 2021, Springer Science + Business Media

    Taku Kobayashi

  58. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

    Article • Nature Reviews Gastroenterology & Hepatology, August 2021, Springer Science + Business Media

    Taku Kobayashi

  59. Can Crohn's disease patients stop anti-TNF?

    Article • Inflammatory Intestinal Diseases, August 2021, Karger Publishers

    Taku Kobayashi

  60. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

    Article • Clinical Gastroenterology and Hepatology, May 2021, Elsevier

    Taku Kobayashi

  61. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, April 2021, Oxford University Press (OUP)

    Taku Kobayashi

  62. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition

    Article • Journal of Gastroenterology and Hepatology, January 2021, Wiley

    Taku Kobayashi

  63. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis

    Article • Journal of Gastroenterology and Hepatology, September 2020, Wiley

    Taku Kobayashi

  64. Capsule endoscopy in inflammatory bowel disease: when and how

    Article • Intestinal Research, July 2020, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  65. Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, June 2020, Wiley

    Taku Kobayashi

  66. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis

    Article • Alimentary Pharmacology & Therapeutics, May 2020, Wiley

    Taku Kobayashi

  67. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis

    Article • Clinical Gastroenterology and Hepatology, May 2020, Elsevier

    Hirotsugu Sakamoto, Taku Kobayashi

  68. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

    Article • Gastroenterology, February 2020, Elsevier

    Taku Kobayashi

  69. Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn’s Disease

    Article • Inflammatory Intestinal Diseases, January 2020, Karger Publishers

    Taku Kobayashi

  70. Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey

    Article • Inflammatory Intestinal Diseases, January 2020, Karger Publishers

    Taku Kobayashi

  71. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

    Article • Intestinal Research, October 2019, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  72. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis

    Article • Journal of Gastroenterology and Hepatology, September 2019, Wiley

    Taku Kobayashi

  73. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

    Article • Intestinal Research, April 2019, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  74. Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease

    Article • PLOS One, February 2019, PLOS

    Taku Kobayashi

  75. Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

    Article • Intestinal Research, January 2019, Korean Association for the Study of Intestinal Diseases (KAMJE)

    Taku Kobayashi

  76. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More

    Article • Inflammatory Intestinal Diseases, January 2019, Karger Publishers

    Taku Kobayashi

  77. Th17 plasticity and its relevance to inflammatory bowel disease

    Article • Journal of Autoimmunity, February 2018, Elsevier

    Taku Kobayashi

  78. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West

    Article • Inflammatory Intestinal Diseases, January 2018, Karger Publishers

    Taku Kobayashi

  79. Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

    Article • Inflammatory Intestinal Diseases, January 2018, Karger Publishers

    Taku Kobayashi

  80. Advances in Endoscopy in Inflammatory Bowel Disease

    Article • January 2018, Springer Science + Business Media

    Taku Kobayashi

  81. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome

    Article • PLOS One, September 2017, PLOS

    Taku Kobayashi

  82. Endoscopic Indices for Ulcerative Colitis

    Article • May 2017, Springer Science + Business Media

    Taku Kobayashi

  83. Treatment Options after Anti-TNF Failure

    Article • January 2015, Karger Publishers

    Taku Kobayashi